Oral News and Research

RSS

Viral toxin causes release of serotonin leading to vomiting

It is well known that viruses like rotavirus and norovirus are behind the majority of stomach infections. But it was unclear how vomiting developed, and the treatments available were oral fluid replacement and intravenous drips to prevent dehydration of the body.

18 Jul 2011

Research roundup: Putting good science into practice; shifting hospital costs; finding savings in Mass.

In 2006, researchers published a widely reported study showing that for many patients who had suffered a heart attack more than 24 hours before and had a blocked coronary artery, certain heart procedures, such as balloon angioplasty and the insertion of stents, were no more effective than drugs alone. In 2007, the American Heart Association and the American College of Cardiology issued guidelines urging doctors to not use such treatments in those patients.

16 Jul 2011

IOM releases second report on oral health

On July 13, the Institute of Medicine (IOM) released a second report on oral health, Improving Access to Oral Health Care for Vulnerable and Underserved Populations.

15 Jul 2011

Simple dental algorithm can effectively identify patients with unrecognized diabetes

In a study, Identification of unrecognized diabetes and pre-diabetes in a dental setting, published in the July 2011 issue of the Journal of Dental Research, researchers at Columbia University College of Dental Medicine found that dental visits represented a chance to intervene in the diabetes epidemic by identifying individuals with diabetes or pre-diabetes who are unaware of their condition.

15 Jul 2011

CVS Caremark adds Access' MuGard to pharmacy benefit network

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.

15 Jul 2011

BioMarin commences BMN 673 Phase 1 trial in hematological malignancies

BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.

15 Jul 2011

NHS facing heavier loads as waiting times rise

According to Sir Richard Thompson, President of the Royal College of Physicians, health service providers are struggling to cope with rising demand especially among the elderly, with the result that planned tests and operations are being delayed. He made his statement as Department of Health statistics showed the proportion of inpatients waiting more than 18 weeks for treatment has risen by 29 per cent since the general election, with those needing orthopedic or brain surgery experiencing the worst delays.

14 Jul 2011

New Tamiflu anti-viral flu medication in lower concentration

When flu season arrives this fall, a liquid form of Tamiflu—the most widely used anti-viral flu medication—will be available in a new, lower concentration to reduce the possibility of medication errors.

14 Jul 2011

UCLA establishes new reconstructive transplantation program

In a major step into a new transplantation frontier, UCLA has established a first-of-its-kind program to restore functionality and enhance quality of life for people who have suffered severe trauma or other disfiguring injuries to the upper extremities, face or abdomen.

13 Jul 2011

Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension

Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

13 Jul 2011

Sinapis completes first clinical trial of lead drug for stroke and traumatic brain injury

Sinapis Pharma, Inc. is pleased to announce that it has completed its first clinical trial in the development of its lead drug for the treatment of stroke and traumatic brain injury.

11 Jul 2011

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland, announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners.

11 Jul 2011

Generex announces convertible preferred stock securities purchase agreement

Generex Biotechnology Corporation today announced that it entered into a securities purchase agreement with certain institutional investors on July 8, 2011.

11 Jul 2011

NewYork-Presbyterian Hospital offers two new treatment options for cancer patients

NewYork-Presbyterian Hospital has two new treatment options for patients with brain tumors and other cancers -- a next-generation radiosurgical Gamma Knife and linear accelerator.

From Elekta 11 Jul 2011

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Sanofi and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif in patients with relapsing-remitting multiple sclerosis.

11 Jul 2011

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

Generex Biotechnology Corporation today announced preliminary clinical results of two major trials using the Generex Oral-lyn formulation that will be used for registration and marketing.

11 Jul 2011

History of cancer increases risk for developing blood clotting issues following knee arthroscopy

A history of cancer was a significant risk factor for developing blood clotting issues following knee arthroscopy, according to a study being presented at the American Orthopaedic Society for Sports Medicine's Annual Meeting in San Diego. Researchers from the Mayo Clinic in Rochester, Minnesota analyzed the records of more than 12,000 patients who had undergone the common knee procedure.

8 Jul 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

InterMune today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis.

8 Jul 2011

Gum disease linked to infertility

According to experts gum disease may reduce the chances of getting pregnant. Poor oral health is as bad for fertility as obesity - delaying conception by about two months says latest research.

7 Jul 2011

Oral News and Research

Viral toxin causes release of serotonin leading to vomiting

Research roundup: Putting good science into practice; shifting hospital costs; finding savings in Mass.

IOM releases second report on oral health

Simple dental algorithm can effectively identify patients with unrecognized diabetes

CVS Caremark adds Access' MuGard to pharmacy benefit network

BioMarin commences BMN 673 Phase 1 trial in hematological malignancies

NHS facing heavier loads as waiting times rise

New Tamiflu anti-viral flu medication in lower concentration

UCLA establishes new reconstructive transplantation program

Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension

Sinapis completes first clinical trial of lead drug for stroke and traumatic brain injury

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

Generex announces convertible preferred stock securities purchase agreement

NewYork-Presbyterian Hospital offers two new treatment options for cancer patients

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

History of cancer increases risk for developing blood clotting issues following knee arthroscopy

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

Gum disease linked to infertility

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News